Consolidated Statements of Changes In Stockholders’ Deficit (Unaudited) - USD ($)	Stockholders’ Deficit Common Stock	Additional Paid-in Capital	Total Accumulated Deficit	Mezzanine Equity	Total
Balance at Dec. 31, 2019	$ 7	$ 44,465,695	$ (91,130,414)	$ 40,070,108	$ (46,664,712)
Balance (in Shares) at Dec. 31, 2019	743,513
Stock based compensation		114,457			114,457
Net loss			(3,159,802)		(3,159,802)
Balance at Jun. 30, 2020	$ 7	44,580,152	(94,290,216)	40,070,108	(49,710,057)
Balance (in Shares) at Jun. 30, 2020	743,513
Balance at Dec. 31, 2020	$ 7	44,727,164	(97,322,784)	40,070,108	(52,595,613)
Balance (in Shares) at Dec. 31, 2020	743,513
Stock based compensation		5,092,248			5,092,248
Issuance of Common Shares	$ 9	23,442			23,451
Issuance of Common Shares (in Shares)	813,125
Preferred Stock conversion into common stock	$ 1,070	40,069,037		(40,070,108)	40,070,107
Preferred Stock conversion into common stock (in Shares)	107,032,771
Notes payable and accrued interest conversion into common stock	$ 989	10,638,627			$ 10,639,616
Notes payable and accrued interest conversion into common stock (in Shares)	98,890,380				1,000
Preferred Stock C exchange for Nanomix Common Stock	$ (2,075)	(14,668,558)		14,670,633	$ (14,670,633)
Preferred Stock C exchange for Nanomix Common Stock (in Shares)	(207,479,789)
Merge with Boston Therapeutics	$ 916,915	(4,782,604)		963,964	(3,865,689)
Merge with Boston Therapeutics (in Shares)	916,914,554
Loss on debt modification		2,385,204			2,385,204
Net loss			(4,791,552)		(4,791,552)
Balance at Jun. 30, 2021	$ 916,915	$ 83,484,560	$ (102,114,336)	$ 15,634,597	$ (17,712,861)
Balance (in Shares) at Jun. 30, 2021	916,914,554